Mindray Announces Preliminary 2008 Operating Results

SHENZHEN, China, Jan. 12 /PRNewswire-Asia-FirstCall/ -- Mindray Medical
International Limited (NYSE: MR), a leading developer, manufacturer and
marketer of medical devices worldwide, today announced selected preliminary,
unaudited results for the fiscal year ended December 31, 2008. The
preliminary results reported below include the results of operations of the
patient monitoring business acquired from Datascope ("DPM") starting from May
1, 2008.
Preliminary 2008 Operating Results
For the year ended December 31, 2008, Mindray expects net revenues to be
in the range of US$540 million to US$550 million, compared to US$294.3 million
in 2007, or 84% to 87% year-over-year growth. Based on the estimated full
year revenue range, fourth quarter 2008 revenue grew 76% to 87% year-over-year
despite a challenging global operating environment that included volatile
foreign exchange fluctuations, a slow down in hospital spending and credit
freezes.
Based on the estimated full year revenue, the company anticipates the 2008
non-GAAP diluted EPS to be no less than US$1.16, compared to US$0.79 in 2007,
or 47% year-over-year growth. The estimated non-GAAP diluted EPS is based on
the assumption that Mindray's Shenzhen subsidiary receives a preferential
income tax rate at 15% as a qualified "New and Hi Tech Enterprise." The
subsidiary has already received approval of such qualification from the
Shenzhen local government, and the Company does not anticipate any delay in
closing the process from the central government level in the near future.
"Despite the recent unprecedented and challenging global environment,
Mindray maintained its focus on outstanding execution and operational
excellence," commented Mr. Xu Hang, Mindray's chairman and co-chief executive
officer. "As a result, we achieved excellent growth across all product lines
and geographies throughout the fourth quarter. Additionally, we continued to
improve operating performance, driving very strong earnings growth in 2008 and
our vertically integrated model and sensible expense controls have allowed us
to focus on generating cash flow and improving our operating margins."
"We are well positioned as we head into 2009 and look to grow market share
in the coming year," added Mr. Li Xiting, Mindray's president and co-chief
executive officer. "Despite broader economic uncertainties, we are confident
about achieving overall revenue growth of at least 20 percent based on the
current foreign exchange rates. We strive to hold steady gross margins with
targeted improvements in operating margins. We expect our growth to primarily
be driven by the continued expansion and improvement in our product mix and
strengthened distribution worldwide. Additionally, we look forward to the
release of seven to nine new products this year, including the launch of our
first jointly developed products with DPM. Overall, we believe that our
ability to be nimble and closely manage costs allows us to pass savings to our
customers. We look forward to continuing to provide high-quality and
affordable medical devices to doctors and hospitals around the world in 2009."
Mindray's preliminary 2008 results are unaudited and remain subject to the
finalization of the company's year-end closing, reporting and audit processes.
The company noted that 2009 full-year guidance will be provided in the
fourth quarter and 2008 year-end earnings announcement.
About Mindray
Mindray is a leading developer, manufacturer and marketer of medical
devices worldwide. Established in 1991, Mindray offers a broad range of
products across three primary business segments: patient monitoring & life
support products, in-vitro diagnostic products and medical imaging systems.
Mindray is globally headquartered in Shenzhen, China, with U.S. headquarters
in Mahwah, New Jersey. Mindray also has another 12 international sales and
service offices in Amsterdam, Frankfurt, Istanbul, London, Mexico City,
Moscow,
Mumbai, Paris, Sao Paolo, Seattle, Toronto and Vancouver. For more
information, please visit http://www.mindray.com .
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Statements that are not historical facts, including
statements about Mindray's anticipated net revenues and earnings per share for
2008, 15% preferential income tax rate for 2008, growth of market share in
2009, growth of net revenues in 2009, continued expansion and improvement in
product mix, strengthened distribution, and the release of new products are
forward-looking statements. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual results
due to a variety of factors. The anticipated results for 2008 remain subject
to the finalization of Mindray's year-end closing, reporting, and audit
processes, particularly as related to accrued expenses, income taxes, share-
based compensation expenses, and expense and/or amortization of intangible
assets. The financial information contained in this release should be read in
conjunction with the consolidated financial statements and notes thereto
included in our public filings with the Securities and Exchange Commission.
For a discussion of other important factors that could adversely affect our
business, financial condition, results of operations and prospects, see "Risk
Factors" beginning on page 6 of our annual report on Form 20-F, filed on June
30, 2008. Our results of operations for the fourth quarter of 2008 and for
fiscal year 2008 are not necessarily indicative of our operating results for
any future periods. Any projections in this release are based on limited
information currently available to us, which is subject to change. Although
such projections and the factors influencing them will likely change, we will
not necessarily update the information. Such information speaks only as of
the date of this release.
Use of Non-GAAP Financial Measures
The company has announced its expected diluted earnings per share for full
year 2008 on a non-GAAP basis.
Because the estimated earnings per share is subject to the finalization of
the company's year-end closing, reporting, and audit processes, the company
has not yet finalized with any certainty the numbers required to provide a
specific non-GAAP to US GAAP reconciliation. A reconciliation of non-GAAP
results of operations measures to the nearest comparable GAAP measures will be
provided with the company's audited financial results and will be adjusted for
the effects of share-based compensation, inventory fair value adjustments,
restructuring or any one-time charge, amortization of acquired assets and in
related tax impact.
For more information, please visit http://www.mindray.com .

For investor and media inquiries, please contact:

In the U.S:
Evan Smith, CFA
FD
Tel: +1-212-850-5606
Email: evan.smith@fd.com

John Capodanno
FD
Tel: +1-212-850-5705
Email: john.capodanno@fd.com

In China:
Susan Du
Mindray Medical International Limited
Tel: +86-755-2658-2518
Email: susan.du@mindray.com

SOURCE Mindray Medical International Limited

In the U.S: Evan Smith, CFA of FD, +1-212-850-5606, or evan.smith@fd.com; Or
John Capodanno of FD, +1-212-850-5705, or john.capodanno@fd.com; Or In China:
Susan Du of Mindray Medical International Limited, +86-755-2658-2518, or
susan.du@mindray.com